ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Prophylaxis with human coagulation factor X in an adolescent girl with hereditary major Stuart factor deficiency.

F. ZEKRE1, F. TARDY2, A. BIGUET PETIT JEAN3, S. THOUVENIN3, C. LEGENDRE3, P. NOYEL3, P. DE MAZANCOURT4, B. TARDY3, C. Berger5

1Chu Saint Etienne, SAINT-ETIENNE, Rhone-Alpes, France, 2CHU Saint-Etienne, SAINT-ETIENNE, Rhone-Alpes, France, 3CHU SAINT-ETIENNE, SAINT-ETIENNE, Rhone-Alpes, France, 4Laboratoire de biologie moléculaire, Hôpital Ambroise Paré (APHP), UMR1179 Paris Saclay University, BOULOGNE-BILLANCOURT, Ile-de-France, France, 5Hemophilia CRC Hospital, INSERM, U 1059, Jean Monnet University,, Saint-Etienne, Rhone-Alpes, France

Abstract Number: PB0703

Meeting: ISTH 2022 Congress

Theme: Hemophilia and Rare Bleeding Disorders » Rare Bleeding Disorders

Background: FX or Stuart Factor deficiency is a rare constitutional hemorrhagic disorder of autosomal recessive transmission. Its incidence is estimated at 1/1,000,000 inhabitants. The hemorrhagic phenotype is variable. Twenty-seven cases are listed in the France Coag registry (inclusion criteria: FX < 10%) in 2021.

Aims: To describe prophylaxis with a specific human product.

Methods: We report the case of a young girl, 18 years old, with a major factor X deficiency.

Results: She presented with rectal bleeding at 15 days of age, which prompted a coagulation assay showing a prothrombin index < 5%, APTT 102 s, factor X < 1%, and factor VII 20%. Factor V and VII normalized with age. Parents were first-degree relatives of Algerian origin, both had respectively factor X 46% and 59%, and the father also had heterozygous factor VII deficiency (55%). Our case subject did not identify the genetic mutation (NGS and MLPA). At the age of 4, she presented twice with hemarthrosis of the left knee, motivating the introduction of prophylaxis with human prothrombin complex (HPC) (20IU/kg once a week). The recuperation rate was 1.9%. Later, her first menstrual period leads to anemia, requiring tranexamic acid and iron supplementation. At 16, we suggested switching to COAGADEX prophylaxis (plasma-derived blood coagulation factor X concentrate) 25 IU/kg once a week. We performed a pharmacokinetics assay; the peak 15 minutes later was 65% of factor X, maintained at 63% at T1 hour, and residual level one week later was 2%. The recuperation rate was 2.5 %. For 18 months, this young girl has been pleased with this product. Injection time was faster than with HPC (1 minute 30 sec versus 20 minutes), and she did not have any recurrence of anemia.

Conclusion(s): COAGADEX, pure human coagulation factor X, could be an exciting alternative for prophylaxis in factor X deficiency.

To cite this abstract in AMA style:

ZEKRE F, TARDY F, BIGUET PETIT JEAN A, THOUVENIN S, LEGENDRE C, NOYEL P, DE MAZANCOURT P, TARDY B, Berger C. Prophylaxis with human coagulation factor X in an adolescent girl with hereditary major Stuart factor deficiency. [abstract]. https://abstracts.isth.org/abstract/prophylaxis-with-human-coagulation-factor-x-in-an-adolescent-girl-with-hereditary-major-stuart-factor-deficiency/. Accessed October 2, 2023.

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/prophylaxis-with-human-coagulation-factor-x-in-an-adolescent-girl-with-hereditary-major-stuart-factor-deficiency/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley